OnabotulinumtoxinA (Botox®) and AbobotulinumtoxinA (Dysport®) in Treating Essential Blepharospasm Long Term Results

Amaç: Esansiyel blefarospazm tedavisinde Botox® ve Dysport® uygulamasının etkinlik ve güvenilirliğinin karşılaştırılması.Yöntemler: Esansiyel blefarospazm tanılı 100 göz çalışmaya dahil edildi. Çalışma retrospektif, randomize karşılaştırmalıdır. Atipik blefarospazmı olanlar, levator palpebra kas inhibisyonu olanlar, Myastenia Graves hastalığı olanlar, ALS hastalığı olanlar, nöromuskuler hastalığı olanlar ve hamile olanlar çalışma dışı bırakıldı. Blefarospazmın ciddiyeti "severity of spasm" (SS), göz kapağı açma zorluğu "closing force of eyelids" (CF) ve fonksiyonel vizüel statü "functional visual status" (FVS) açısından derecelendirilerek başarı değerlendirildi. SS, CFV ve FVS skorlarında azalma başarı kabul edildi.Bulgular: Esansiyel blefarospazmı olan 49 göze Botox (yaş ortalaması 52,1±9,8 yaş), 51 göze Dysport (yaş ortalaması 51,7±10,4 yaş) uygulandı. Enjeksiyon sonrası 4. haftadaki başarı oranı Botox®, grubunda %91,8, Dysport® grubunda 90,1 bulundu. İki grup arasında istatistiksel olarak anlamlı bir fark saptanmadı (p>0,05). İki yıllık takip sonucunda Botox grubunda 41 göz takipte kaldı ve %87,8 (36 göz) oranında başarı sağlandı. Dysport grubunda 44 göz takipte kaldı, %86,4 (38 göz) oranında başarı sağlandı. Aralarındaki fark istatistiksel olarak anlamlı bulunmadı (p>0,05). İlaç yan etkileri açısından, Botox grubunda 1 hastada kuru göz ve baş ağrısı, 1 hastada pitoz görüldü. Dysport grubunda ise 2 hastada pitoz görüldü. İlaçların yan etkileri oranlarının benzer olduğu görüldü.Sonuç: Esansiyel blefarospazm tedavisinde Botox ve Dysport karşılaştırıldığında her iki yöntem de etkin ve güvenilir bulunmuştur.

Esansiyel Blefarospazm Tedavisinde Botox® ve Dysport®un Uzun Dönem Sonuçları

Objective:To compare the clinical characteristics and outcomes of patients with blepharospasm who were treated with OnabotulinumtoxinA (Botox®) and AbobotulinumtoxinA (Dysport®).Methods: A total of 100 eyes of 78 patients who were diagnosed with blepharospasm were evaluated during a retrospective, randomized, parallel group study. The severity of spasm, eyelid closing force, and functional visual status scores were used as quantitative measures of the change in clinical status. Side effects (ptosis, dry eye, ocular foreign body sensation, headache, eyelid edema, pain, and ocular irritation) were collected using a systematic questionnaire.Results: Both Botox® and Dysport® groups produced similar clinical efficacy and tolerability. Success rates at 4 weeks post-injection were 91.8% in the Botox® group and 90.1% in the Dysport group. With respect to success rates, no statistically significant difference was detected between groups. In the Botox® group, 2 years of follow-up was completed in 41 eyes. Success was achieved in 36 eyes (87.8%). In the Dysport® group, 2 years of follow-up was completed in 44 eyes. Success was achieved in 38 eyes (86.4%). The difference was not statistically significant (p>0.05). There were no clinically relevant differences between Botox® and Dysport® groups with regard to safety parameters. Both Botox® and Dysport®were effective and safe in treating blepharospasm.Conclusion: This study suggests that both Botox® and Dysport® do not differ from each other in terms of potency and adverse reaction profile.

___

1. Hallett M, Daroff RB. Blepharospasm: report of a workshop. Neurology 1996; 46: 1213-8. [CrossRef]

2. Defazio G, Livrea P. Epidemiology of primary blepharospasm. Mov Disord 2002; 17: 7-12. [CrossRef]

3. Reimer J, Gilg K, Karow A, Esser J, Franke GH. Health related quality of life in blepharospasm or hemifacial spasm. Acta Neurol Scand 2005; 111: 64-70. [CrossRef]

4. Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 1985; 103: 347-50. [CrossRef]

5. Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S; for the NT 201 Blepharospasm Study Team. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006; 113: 303-12. [CrossRef]

6. Elston JS, Russell RW. Effect of treatment with botulinum toxin on neurogenic blepharospasm. Br Med J (Clin Res Ed) 1985; 290: 1857-9. [CrossRef]

7. Marion MH, Sheehy S, Sangla S, Soulayrol S. Dose standardization of botulinum toxin. J Neurol Neurosurg Psychiatry 1995; 59: 102-3. [CrossRef]

8. Khoo HM, Kim JC, Khoo BS. Treatment of blepharospasm and hemifacial spasm with Botulinum toxin A (Oculinum®). J Korean Ophthalmol Soc 1990; 31: 59-68.

9. Kim JC, Kim WS, Ahn SK, Shyn KH. Clinical studies in patients with essential blepharospasm and with hemifacial spasm. J Korean Ophthalmol Soc 1991; 32: 837-43.

10. Jost WH, Kohl A. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. J Neurol 2001; 248: 21-4. [CrossRef]

11. MacAndie K, Kemp E. Impact on quality of life of botulinum toxin treatments for essential blepharospasm. Orbit 2004; 23: 207-10. [CrossRef]

12. Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, et al. Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev 2005; CD004900.

13. Fahn S, List T, Moslowitz C, Brin M, Bressman SB, Burke RE, et al. Double-blind controlled study of botulinum toxin for blepharospasm. Neurology 1985; 35 (Suppl 1): 271-2.

14. Sampaio C, Ferreira JJ, Simoes F, Rosas MJ, Magalhaes M, Correia AP, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A - Dysport and Botox-assuming a ratio of 4:1. Mov Disord 1997; 12: 1013-8. [CrossRef]

15. Nüssgens Z, Roggenkämper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 1997; 235: 197-9. [CrossRef]

16. Vergilis-Kalner IJ. Same-patient prospective comparison of botox versus dysport for the treatment of primary axillary hyperhidrosis and review of literature. J Drugs Dermatol 2011; 10: 1013-5.

17. Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotox Res 2009; 15: 224-31. [CrossRef]

18. Bihari K. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm. Curr Med Res Opin 2005; 21: 433-8. [CrossRef]

19. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double blind, randomized, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002; 72: 459-62.

20. Dutton JJ, Buckley EG. Long-term results and complications of botulinum a toxin in the treatment of blepharospasm. Ophthalmology 1988; 95: 1529-34. [CrossRef]

21. Price J, Farish S, Taylor H, O'Day J. Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections. Ophthalmology 1997; 104: 865-8. [CrossRef]

22. Price J, O'Day J. Efficacy and side effects of botulinum toxin treatment for blepharospasm and hemifacial spasm. Aust N Z J Ophthalmol 1994; 22: 255-60. [CrossRef]

23. Snir M, Weinberger D, Bourla D, Kristal-Shalit O, Dotan G, Axer-Siegel R. Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm. Am J Ophthalmol 2003; 136: 99-105. [CrossRef]

24. Frueh BR, Nelson CC, Kapustiak JF, Musch DC. The effect of omitting botulinum toxin from the lower eyelid in blepharospasm treatment. Am J Ophthalmol 1988; 106: 45-7. [CrossRef]

25. Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type a injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 2005; 53: 407-15. [CrossRef]

26. Kenney C, Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm 2008; 115: 585-91. [CrossRef]

27. European Medicines Agency (2005) Guideline on similar biological medicinal products. Available at: http://www.emea.europa.eu/pdfs/ human/biosimilar/043704en.pdf. Accessed March 25, 2012.

28. Hellman A, Torres-Russotto D. Botulinum toxin in the management of blepharospasm: current evidence and recent developments Ther Adv Neurol Disord 2015; 8: 82-91.

29. Kollewe K, Mohammadi B, Köhler S, Pickenbrock H, Dengler R, Dressler D. Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®. J Neural Transm 2015; 122: 427-31. [CrossRef]

30. Chundury RV, Couch SM, Holds JB. Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm. Ophthal Plast Reconstr Surg 2013; 29: 205-7. [CrossRef

___

JAREM
  • ISSN: 2146-6505
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 2011
  • Yayıncı: Galenos Yayınevi

10b5.5b